3Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors[J].Eur J Cancer,2006 ;42 ( 8 ) : 1093-103.
4Blanchard DK, Bubbe JM, Metz CE, et al. Tumors of the small intestine [J]. World J Snrg,2000;24(4) :421-42.
5Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors : a consensus approach [J].Int J Surg Pathol, 2002 ; 10 (2) 81-9.
6Tran T, Davila JA, EI-Seraqc HB. The epidemiology of malignant gastro- intestinal stromal tumors:an analysis of 1,458 cases from 1992 to 2000 [J].Am J Castroenterol,2005 ; 100( 1 ) : 162-8.
7Buckley JA, Fishman EK. CT evaluation of small bowel neoplasm:spectrum of disease [J]. Radiographics, 1998 ; 18 ( 2 ) : 379 -592.
8Miettinen M, Sobin LH, Sarlomo-Rikala M, et al. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 ( KIT ) [J]. Mod Pathol,2000 ; 13 ( 10 ) : 1134-42.
9Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors[J]. Eur J Surg Oncol, 2004 ;30(10) : 1098-103.
10Davila RE, Faigel DO. GI stromal tumors[J]. Gastrointest Endosc, 2003 ;58( 1 ) :80-8.
